Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news

I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many knew it would — with the company’s experimental drug for Alzheimer’s…